Posted by Michael Wonder on 04 Dec 2024
Alnylam announces US FDA acceptance of supplemental new drug application for vutrisiran for the treatment of ATTR amyloidosis with cardiomyopathy
25 November 2024 - PDUFA date set for 23 March 2025.
Alnylam Pharmaceuticals today announced that the US FDA has accepted for review the Company’s supplemental new drug Application for vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy.
